Avelumab and Merkel Cell Carcinoma: Medical Literature on Associated Risk

From General Health to Targeted Pharmacovigilance

The legacy of general health and science information has long provided a foundational framework for understanding broad wellness principles, disease prevention, and the biological underpinnings of human health. Within this expansive domain, public health messaging and clinical education have traditionally emphasized lifestyle factors, environmental influences, and the importance of evidence-based medical interventions. This heritage established a baseline for how populations and practitioners interpret risk, particularly in relation to pharmaceutical agents and their intended therapeutic benefits. As medical science advances, the scope of health information necessarily narrows from general principles to specific clinical contexts, including the nuanced evaluation of drug safety profiles. In the realm of oncology, where immunomodulatory therapies such as Avelumab are employed, the transition from general health literacy to targeted pharmacovigilance becomes critical. Avelumab, a programmed death-ligand 1 inhibitor, is utilized in the treatment of Merkel cell carcinoma, a rare but aggressive skin cancer. The clinical administration of this agent introduces a distinct occupational exposure concern for healthcare workers involved in its preparation, handling, and delivery. Shifting focus from the general health context of cancer treatment to the specific risks of occupational exposure, the potential for unintended contact with Avelumab—through inhalation, dermal absorption, or needlestick injury—raises questions about secondary carcinogenic risk. This pivot underscores the need to examine whether such exposure could independently contribute to Merkel cell carcinoma development, thereby transforming a therapeutic tool into a workplace hazard requiring rigorous safety protocols.

Avelumab: Mechanism and Therapeutic Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This makes avelumab the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three academic sites in Germany, five patients with metastatic MCC refractory to avelumab were subsequently treated with combined ipilimumab and nivolumab. Three out of five patients responded to this combination therapy according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported that ipilimumab plus nivolumab can be effective in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study further noted that despite advances in systemic therapy, about half of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Safety Profile and Immune-Related Adverse Events

Avelumab, like other checkpoint inhibitors, can cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; the hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that while avelumab is associated with immune-related adverse events, these can often be managed without discontinuing treatment. Regarding causation-related considerations for affected patients, the timeline between avelumab exposure and documented harm is not explicitly detailed in the available evidence. However, the literature indicates that avelumab is used as a treatment for MCC, not as a cause of the disease. The evidence does not support a causal link between avelumab and the development of MCC; rather, avelumab is an approved therapy for existing MCC. The adequacy of warnings regarding avelumab and MCC is reflected in its approved labeling for the treatment of metastatic MCC, which includes information on immune-related adverse events. No evidence suggests that avelumab induces or causes MCC; instead, it is a therapeutic agent for patients already diagnosed with the condition.

Occupational Exposure Considerations

While the therapeutic use of avelumab is well-established, occupational exposure among healthcare workers handling the drug warrants attention. Potential routes of unintended exposure include inhalation of aerosolized particles, dermal absorption, or needlestick injuries during preparation and administration. The current literature does not provide direct evidence linking occupational exposure to avelumab with the development of Merkel cell carcinoma. However, given the drug's mechanism as an immune checkpoint inhibitor, theoretical concerns about immune modulation and carcinogenesis exist. Healthcare institutions should adhere to standard precautions for hazardous drugs, including the use of closed-system transfer devices, personal protective equipment, and proper disposal protocols. Ongoing pharmacovigilance and reporting of any adverse outcomes following occupational exposure are essential to clarify this risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

No, the available evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Avelumab is an approved therapy for treating existing metastatic Merkel cell carcinoma, not a cause of the disease. It works by blocking PD-L1 to enhance the immune response against cancer cells.

What are the risks of occupational exposure to avelumab?

Occupational exposure to avelumab may occur through inhalation, skin contact, or needlestick injury during handling. While no direct evidence links such exposure to Merkel cell carcinoma, healthcare workers should follow standard safety protocols for hazardous drugs, including using closed systems and protective equipment, to minimize any potential risks.

What should I do if I have been exposed to avelumab and later diagnosed with Merkel cell carcinoma?

If you have documented avelumab exposure and a confirmed Merkel cell carcinoma diagnosis, you may request an independent eligibility review through the Information Registry. This process can help assess any potential association and guide further steps.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.